(Reuters) -AstraZeneca said on Tuesday it expects to deliver $80 billion in total revenue by 2030, boosted by the expected launch of 20 new medicines and through growth in its existing oncology, biopharmaceuticals and rare disease portfolio.
The drugmaker said in a statement it would continue to invest in new technologies and platforms that will “shape the future of medicine” beyond 2030.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Krishna Chandra Eluri, Nivedita Bhattacharjee)
